212 related articles for article (PubMed ID: 33634984)
1. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
Zhang C; Lu X; Huang J; He H; Chen L; Liu Y; Wang H; Xu Y; Xing S; Ruan X; Yang X; Chen L; Xu D
Clin Transl Med; 2021 Feb; 11(2):e328. PubMed ID: 33634984
[TBL] [Abstract][Full Text] [Related]
2. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
3. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
4. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Zhang C; Chen L; Liu Y; Huang J; Liu A; Xu Y; Shen Y; He H; Xu D
Theranostics; 2021; 11(8):3676-3693. PubMed ID: 33664855
[No Abstract] [Full Text] [Related]
5. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
6. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.
Tsuruda M; Yoshino H; Okamura S; Kuroshima K; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
PLoS One; 2020; 15(5):e0232545. PubMed ID: 32379831
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
Huang KB; Pan YH; Shu GN; Yao HH; Liu X; Zhou M; Wei JH; Chen ZH; Lu J; Feng ZH; Chen W; Han H; Zheng ZS; Luo JH; Zhang JX
Cancer Lett; 2021 Dec; 523():121-134. PubMed ID: 34626691
[TBL] [Abstract][Full Text] [Related]
10. An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma.
Zhou J; Simon JM; Liao C; Zhang C; Hu L; Zurlo G; Liu X; Fan C; Hepperla A; Jia L; Tcheuyap VT; Zhong H; Elias R; Ye J; Henne WM; Kapur P; Nijhawan D; Brugarolas J; Zhang Q
Mol Cell; 2022 Aug; 82(16):3030-3044.e8. PubMed ID: 35764091
[TBL] [Abstract][Full Text] [Related]
11. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
12. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
14. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
15. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
17. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma.
Xing Q; Li R; Xu A; Qin Z; Tang J; Zhang L; Tang M; Han P; Wang W; Qin C; Du M; Zhang W
Cancer Med; 2019 Jun; 8(6):2886-2896. PubMed ID: 31038847
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
20. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair.
Tan L; Huang Z; Chen Z; Chen S; Ye Y; Chen T; Chen Z
J Chemother; 2023 Feb; 35(1):11-18. PubMed ID: 34927575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]